Absolute Risk of Endometrial Carcinoma During 20-Year Follow-Up Among Women With Endometrial Hyperplasia

University of Maryland, Baltimore, Baltimore, Maryland, United States
Journal of Clinical Oncology (Impact Factor: 17.88). 02/2010; 28(5):788-92. DOI: 10.1200/JCO.2009.24.1315
Source: PubMed

ABSTRACT PURPOSE The severity of endometrial hyperplasia (EH)-simple (SH), complex (CH), or atypical (AH)-influences clinical management, but valid estimates of absolute risk of clinical progression to carcinoma are lacking. Materials and METHODS We conducted a case-control study nested in a cohort of 7,947 women diagnosed with EH (1970-2002) at one prepaid health plan who remained at risk for at least 1 year. Patient cases (N = 138) were diagnosed with carcinoma, on average, 6 years later (range, 1 to 24 years). Patient controls (N = 241) were matched to patient cases on age at EH, date of EH, and duration of follow-up, and they were counter-matched to patient cases on EH severity. After we independently reviewed original slides and medical records of patient controls and patient cases, we combined progression relative risks (AH v SH, CH, or disordered proliferative endometrium [ie, equivocal EH]) from the case-control analysis with clinical censoring information (ie, hysterectomy, death, or left the health plan) on all cohort members to estimate interval-specific (ie, 1 to 4, 5 to 9, and 10 to 19 years) and cumulative (ie, through 4, 9, and 19 years) progression risks. Results For nonatypical EH, cumulative progression risk increased from 1.2% (95% CI, 0.6% to 1.9%) through 4 years to 1.9% (95% CI, 1.2% to 2.6%) through 9 years to 4.6% (95% CI, 3.3% to 5.8%) through 19 years after EH diagnosis. For AH, cumulative risk increased from 8.2% (95% CI, 1.3% to 14.6%) through 4 years to 12.4% (95% CI, 3.0% to 20.8%) through 9 years to 27.5% (95% CI, 8.6% to 42.5%) through 19 years after AH. CONCLUSION Cumulative 20-year progression risk among women who remain at risk for at least 1 year is less than 5% for nonatypical EH but is 28% for AH.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Women with Lynch syndrome have an increased risk of developing colorectal and gynecologic malignancies such as endometrial cancer. Complex hyperplasia has about a 30% risk of developing into endometrial cancer. The aim of this study was to determine the genetic risk for developing endometrial cancer by immunohistochemical staining of premalignant lesions for mutL homolog 1, mutS homolog 2, mutS homolog 6, and postmeiotic segregation increased 2. Twenty cases (n=20) were selected from among patients with available sample blocks for analysis. Clinical information was obtained from medical chart review. Immunohistochemical staining was performed for all of the tumor blocks. Staining was scored based on the intensity (intensity score 0-3) . Among the 20 cases of complex endometrial hyperplasia, 11 (55%) patients showed loss of expression of at least one of the following proteins: mutL homolog 1, mutS homolog 2, mutS homolog 6, or postmeiotic segregation increased 2. Seven (35%) patients were negative for the expression of two or more proteins, and one patient (5%) was negative for the expression of all four proteins. More than half of the patients showed loss of expression of at least one mismatch repair protein in our study population. Genetic risk counseling and further tests are recommended for these patients.
    03/2015; 58(2):106-11. DOI:10.5468/ogs.2015.58.2.106
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since Doll published the first PAF in 1951, it has been a mainstay. Confusion in terminology abounds with regard to these measures. The ability to estimate all of them in case-control studies as well as in cohort studies is not widely appreciated. This article reviews and comments on the historical development of the population attributable fraction (PAF), the exposed attributable fraction (EAF), the rate difference (ID), the population rate (or incidence) difference (PID), and the caseload difference (CD). The desire for PAFs to sum to no more than 100% and the interpretation of the complement of a PAF as the proportion of a rate that can be attributed to other causes are shown to stem from the same problem: a failure to recognize the pervasiveness of shared etiologic responsibility among causes. A lack of appreciation that "expected" numbers of cases and deaths are not actually the numbers to be expected when an exposure or intervention appreciably affects person-time denominators for rates, as in the case of smoking and nonnormal body mass, makes many CD estimates inflated. A movement may be gaining momentum to shift away from assuming, often unrealistically, the complete elimination of harmful exposures and toward estimating the effects of realistic interventions. This movement could culminate in a merger of the academic concept of transportability with the applied discipline of risk assessment. A suggestion is offered to pay more attention to absolute measures such as the rate difference, the population rate difference, and the CD, when the latter can be validly estimated and less attention to proportional measures such as the EAF and PAF. Copyright © 2015 Elsevier Inc. All rights reserved.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim of the study: Our aim was to investigate the expression and the prognostic significance of tumour-associated glycoprotein 72 (TAG-72), which is an epithelial tumour marker, using immunohistochemical methods in the normal, hyperplastic and neoplastic endometrium. Material and methods: The study group comprised of 47 cases with simple non-atypical hyperplasia and normal endometrium (n = 17), complex non-atypical hyperplasia (n = 10), and endometrial adenocarcinoma (n = 21). The epithelial tumour marker TAG-72 was determined by immunohistochemical methods. The location of TAG-72 in the differential diagnosis and its prognostic value were statistically analyzed. Results: The immunoreactivity of the immunohistochemical dye was evaluated in terms of the pattern, intensity and pattern + intensity. The comparison between the three groups showed that there was a significant difference in terms of pattern (p < 0.001), intensity (p < 0.001) and pattern + intensity (p < 0.001). The marker TAG-72 was not found to be a prognostic marker for endometrial adenocarcinoma. Conclusions: The marker TAG-72 is a reliable parameter and marker for the differentiation of the neoplastic endometrium from the non-neoplastic and hyperplastic endometrium. There is a significant relationship between the increasing age and staining pattern of the TAG-72 expression. Still, TAG-72 does not seem to be an independent prognostic factor for the endometrial carcinoma.
    Menopausal Review 06/2013; 3(3):202-206. DOI:10.5114/pm.2013.36583 · 0.38 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014